PL
ARQT icon

Perpetual Ltd’s Arcutis Biotherapeutics ARQT Stock Holding History

Perpetual Ltd’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.1M Buy
1,109,657
+200,111
+22% +$4.66M 0.42% 71
2026
Q1 		$21.4M Sell
909,546
-1,084
-0.1% -$27.7K 0.33% 81
2025
Q4 		$26.4M Sell
910,630
-1,113,976
-55% -$28.5M 0.38% 65
2025
Q3 		$38.2M Buy
2,024,606
+1,998,086
+7,534% +$31.5M 0.47% 54
2025
Q2 		$372K Hold
26,520
– – ﹤0.01% 352
2025
Q1 		$415K Buy
+26,520
New +$374K 0.01% 350

Other funds holding ARQT

PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
WB
WesBanco Bank Wheeling, West Virginia $4.02B AUM 32.62% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
MWS
MFA Wealth Services Thousand Oaks, California $167M AUM 20.54% 1-Year Est. Return

Perpetual Ltd's ARQT Position: Q2 2026 in Review

Perpetual Ltd increased its Arcutis Biotherapeutics (ARQT) stake by 22% in Q2 2026, buying an estimated $4.66M and bringing the position to 1,109,657 shares worth $29.1M. The position accounts for 0.42% of the portfolio, ranked #71.

Perpetual Ltd first reported a position in ARQT in Q1 2025 and has held it in 6 quarters since. The position peaked at $38.2M in Q3 2025. 38 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Perpetual Ltd held 1,109,657 shares of Arcutis Biotherapeutics worth $29.1M as of Q2 2026.
  • Perpetual Ltd bought 200,111 Arcutis Biotherapeutics shares in Q2 2026, an estimated $4.66M.
  • Arcutis Biotherapeutics made up 0.42% of Perpetual Ltd's portfolio in Q2 2026, its #71 holding.
  • Perpetual Ltd first reported a position in Arcutis Biotherapeutics in Q1 2025 and has held it in 6 quarters since.
  • Perpetual Ltd's Arcutis Biotherapeutics position peaked at $38.2M in Q3 2025.
  • 38 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Perpetual Ltd's 13F filing for Q2 2026, filed 15 Jul 2026.